Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

Cyclerion Therapeutics (Nasdaq: CYCN) announced its participation in two upcoming investor conferences.

Rhea-AI Summary

Cyclerion Therapeutics (Nasdaq: CYCN) announced its participation in two upcoming investor conferences. The company will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. ET, with a webcast available on their website. Additionally, an on-demand presentation will be available at the H.C. Wainwright BioConnect Conference on January 11, 2021, at 6:00 a.m. ET. Cyclerion focuses on innovative treatments for serious CNS diseases, notably their lead program, CY6463, aimed at conditions like MELAS and Alzheimer's with vascular pathology.

Argus Session date unavailable

-0.65% session move Open Argus

Details

News Market Reaction – CYCN

The recorded move for CYCN in the trading session of this news was -0.65%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:

• 39th Annual J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021 at 3:40 p.m. ET and a live webcast may be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay will be available for approximately 90 days following the presentation.
• H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021 at 6:00 a.m. ET at the conference website.

About Cyclerion Therapeutics 
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS). Cyclerion’s lead program is CY6463 a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv).

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Cyclerion Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Cyclerion Therapeutics will present a corporate overview on January 14, 2021, at 3:40 p.m. ET.

When will Cyclerion's on-demand presentation be available?

The on-demand presentation at the H.C. Wainwright BioConnect Conference will be available on January 11, 2021, at 6:00 a.m. ET.

What is the focus of Cyclerion Therapeutics in their drug development?

Cyclerion focuses on developing innovative medicines for serious central nervous system diseases.

What is Cyclerion's lead program and its target conditions?

Cyclerion's lead program is CY6463, targeting Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology.